1871P - Temperature-controlled hand-foot cooling combined with compression prevents chemotherapy-induced polyneuropathy (CIPN): A single center, prospective, real-world data collection

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of taxane (Paclitaxel, nab-Paclitaxel, Docetaxel). CIPN could reduce long-term quality of life (Blackley et al, 2019) and result in dose delays, reductions or treatment discontinuations. Temperature-controlled hand-foot cooling (Hilotherapy®) prevents CIPN (Oneda et al. 2020&2021, Coolbrandt et al. 2022). Prospectively collected data of 151 breast cancer patients showed that cooling using 1^st generation cuffs with 30 minutes post-cooling prevents CIPN ≥ 2° in 93,4% of patients undergoing taxane-based chemotherapy (Schaper et al. in prep.). The development of 2^nd generation, combined cooling-compression cuffs, ensures even more effective skin cooling. This raises the question, whether cooling time could be safely reduced.

Methods

We used prophylactic cooling with 2^nd generation cuffs as standard of care during chemotherapy without the recommended 30 minutes post-cooling, due to capacity issues, and investigated the efficacy of the 2^nd generation cuffs regarding prevention of CIPN through surveys. Patients were stratified according to dosing schedule (q1w vs q3w). Follow-up data will be collected to report the sustainability of the results.

Results

181 breast cancer patients completed their taxane-based chemotherapy using 2^nd generation cuffs without post-cooling. 169 (93,4%) patients showed symptoms of CIPN 0-1° and 12 (6,6%) of CIPN 2°. No patient reported grade 3 toxicity. Data collection is still in process and follow-up will be updated to examine the sustainability of the results.

Conclusions

Prophylactic temperature-controlled hand-foot cooling combined with compression (Hilotherapy® 2^nd generation) without the recommended 30 minutes post-cooling effectively prevents the development of severe CIPN ≥ 2°.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

ISI e.V. - International Senology Initiativ.

Disclosure

A. Kostara: Non-Financial Interests, Personal and Institutional, Advisory Board, Study Equipment funding: Hilotherm GmbH. All other authors have declared no conflicts of interest.